Exton, PA-based Frontage Laboratories announced Tuesday that it had completed its acquisition of the bioanalytical and drug metabolism & pharmacokinetics (DMPK) businesses of Accelera S.r.l.
Located in the Lombardy region of Italy, Accelera is a contract research organization that has positioned itself as a niche player in delivering discovery and preclinical studies, as well as clinical bioanalysis to pharma and biotechnology companies, academic institutions and other members of the healthcare sectors.
“Today marks a very significant achievement in the 23-year history of Frontage Laboratories, as we establish a base of operations in continental Europe,” Dr. Abdul Mutlib, CEO of Frontage, said. “We envision this strategic acquisition as a first step in establishing Frontage’s footprint in Europe, with the intent of adding other service areas in the continent. We believe both existing Frontage and Accelera clients stand to benefit greatly by leveraging Frontage’s increasingly global platform. In addition, we are looking forward to partnering with the remaining Accelera business on exciting opportunities to service clients across our organizations.”
Frontage Laboratories is a wholly-owned subsidiary of Frontage Holdings, is a contract research organization that provides integrated science-driven product development services from drug discovery to late phase clinical processes that help biopharmaceutical companies.
“It has been a long-standing goal of Frontage to expand our operations in Europe,” Dr. Song Li, founder and chairman of Frontage said. “We consider ourselves fortunate to capitalize on our outstanding relationship with the Accelera team, which has enabled us to bring our plans to fruition. We are very enthusiastic about working together as we further develop the Frontage platform in Europe, starting from a footprint in the Biopark in Nerviano Lombardy, where Accelera and Nerviano Medical Sciences Srl have already established a long-standing and efficient value chain. As always, our ongoing focus will remain on delivering the highest levels of quality, technology and expertise to our clients.”